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Pituitary adenomas, accounting for 15% of diagnosed intracranial neoplasms, are
usually benign and pharmacologically and surgically treatable; however, the critical
location, mass effects and hormone hypersecretion sustain their significant morbidity.
Approximately 35% of pituitary tumors show a less benign course since they are
highly proliferative and invasive, poorly resectable, and likely recurring. The latest
WHO classification of pituitary tumors includes pituitary transcription factor assessment
to determine adenohypophysis cell lineages and accurate designation of adenomas,
nevertheless little is known about molecular and cellular pathways which contribute
to pituitary tumorigenesis. In malignant tumors the identification of cancer stem cells
radically changed the concepts of both tumorigenesis and pharmacological approaches.
Cancer stem cells are defined as a subset of undifferentiated transformed cells from
which the bulk of cancer cells populating a tumor mass is generated. These cells are
able to self-renew, promoting tumor progression and recurrence of malignant tumors,
also conferring cytotoxic drug resistance. On the other hand, the existence of stem
cells within benign tumors is still debated. The presence of adult stem cells in human
and murine pituitaries where they sustain the high plasticity of hormone-producing
cells, allowed the hypothesis that putative tumor stem cells might exist in pituitary
adenomas, reinforcing the concept that the cancer stem cell model could also be
applied to pituitary tumorigenesis. In the last few years, the isolation and phenotypic
characterization of putative pituitary adenoma stem-like cells was performed using a
wide and heterogeneous variety of experimental models and techniques, although the
role of these cells in adenoma initiation and progression is still not completely definite. The
assessment of possible pituitary adenoma-initiating cell population would be of extreme
relevance to better understand pituitary tumor biology and to identify novel potential
diagnostic markers and pharmacological targets. In this review, we summarize the most
updated studies focused on the definition of pituitary adenoma stem cell phenotype
and functional features, highlighting the biological processes and intracellular pathways
potentially involved in driving tumor growth, relapse, and therapy resistance.
Keywords: pituitary, cancer stem cells, self-renewal, tumorigenesis, drug sensitivity
Würth et al. Pituitary Adenoma Stem Cells
ADULT STEM CELLS VS. CANCER STEM
CELLS
Tissue-resident adult stem cells are undifferentiated cells able
to self-renew for long periods by asymmetric division, and to
generate the bulk of differentiated cells within tissues to support
organ repair and regeneration (1). Adult stem cells fate and
functioning greatly depend on the stem cell niche, a specialized
surrounding microenvironment which control stem cell homing
and the balance between self-renewal and differentiation (2). In
general, healthy stem cells show a stable diploid genome, slow
growth rate or quiescence, granting their persistence for the
lifetime of the organism, and express pattern of surface markers
distinctive for stem cells in different organs (3). Before having a
complete phenotype maturation, stem cells develop into partly
differentiated progenitors or committed cells (4).
Tumors are characterized by cell heterogeneity including
cell populations with stem-like features, whose identification
have revolutionized the concept of cancer origin: according to
the hierarchical model of tumorigenesis, tumors arise from a
pool of self-renewing cancer stem cells (CSCs) which initiate
and maintain tumor growth, and establish a differentiation
hierarchy by generating non-tumorigenic differentiated
cancer cell bulk. Stem cells, immature progenitors, or more
differentiated progenies that develop oncogenic mutations,
followed by the accumulation of multiple genetic, epigenetic
and microenvironmental hits, acquire a fully transformed
phenotype which, associated to typical stem cell features, gives
origin to tumor specific CSCs (5). Importantly, hierarchical
organization is reversible due to cell plasticity of differentiated
cancer cells which can de-differentiate to regenerate CSCs
and sustain tumor progression (6). CSCs have been identified
in both hematopoietic and solid tumors, showing unlimited
self-renewal and proliferative potential also in the absence
of extracellular cues, pluripotency, expression of stemness
markers, and aneuploidy. CSCs, as well as normal stem cells,
have improved DNA-repair and detoxification mechanisms,
and high activity of anti-apoptotic and pro-survival pathways.
Thus, CSCs are able to resist to anticancer drugs determining
chemoresistance, and supporting tumor progression and relapse
(7). Migratory capacity is also a common feature of normal stem
cells and it is functional to cell homing and tissue regeneration
(8), whereas the high motility of CSCs favors their invasive and
metastatic capacity. Differently from normal stem cells, during
tumor progression CSCs build their own altered niche, recruiting
neighboring stromal, mesenchymal, endothelial, and immune
cells; this delicate microenvironment further protects and favors
CSC maintenance and proliferation (9). Although normal stem
Abbreviations: HES, Hairy Enhancer of Split; HEY, HES-related with YRPW
motif; Smo, Smoothened; Ptch1, Patched; GLI, Gli zinc finger transcription factors;
LATS1/2, large tumor suppressor homolog 1 and 2; YAP, Yes-associated protein;
TAZ, Transcriptional co-activator with PDZ bindingmotif; TEAD, Transcriptional
enhanced associate domain; FZD, Frizzled; LEF, Lymphoid enhancer factor;
LGR, Leucine rich repeat containing G protein-coupled receptor; TCF7L1,
Transcription factor 7 like 1; CXCR4/7, CX-chemokine receptors 4 and 7;
TGFRB2, Transforming Growth Factor Beta-Receptor 2; TWIST1, Twist-related
protein 1; ZEB1, Zinc-finger E-box-binding homeobox 1.
cells and CSCs share key signaling pathways and transcription
factors which regulate self-renewal and determine cell fate
(Wnt/β-catenin, BMPs, Sonic hedgehog (SHH), Notch, Sox2,
Oct4, Nanog, Bmi-1, PI3K/Akt cascade), in normal stem cells
this signaling tightly depends on extrinsic growth factor signals,
while in CSCs, dysregulation or hyperactivation of transcription
factor-mediated pathways drives abnormal self-renewal and
tumorigenesis, sustaining differentiation into highly proliferative
cancer cells (10).
Normal stem cells can be experimentally identified and
isolated according to the expression of specific stem cell antigens
(e.g., SOX2, NANOG, OCT4, CD44) and the in vitro clonogenic
and differentiation potentials; however, CSC characterization,
beside these parameters, requires the establishment of the
tumorigenic potential in in vivomodels.
CSC-dependent intratumor cellular heterogeneity has been
typically considered the basis for malignant tumor development,
progression and spreading. However, in recent years, several
studies reported the characterization of CSC-like subpopulation
also in benign tumors [i.e., meningiomas (11) and pituitary
adenomas (12)], highlighting the possibility that, similarly to
normal organogenesis during development, tumorigenesis of all
kinds of neoplasia, either benign or malignant, requires the
activity of stem-like cell subpopulations (13).
AN OVERVIEW OF THE HUMAN PITUITARY
GLAND
Pituitary is the main endocrine regulatory gland, which transmit
hypothalamic signals to target organs through systemic hormone
secretion. It is composed of anterior (adenohypophysis) and
posterior (neurohypophysis) lobes with distinct embryological
origin, morphology and functions; the endocrine center is
adenohypophysis whose specialized cell types are identified
according to the secreted hormone: corticotroph cells produce
adrenocorticotropic hormone (ACTH); gonadotrophs,
follicle-stimulating (FSH) and luteinizing (LH) hormones;
lactotrophs, prolactin (PRL); somatotrophs, growth hormone
(GH), and thyrotrophs, thyroid-stimulating hormone (TSH).
Undifferentiated pituitary stem cells (PSCs) exist within anterior
pituitary and give rise to the three main progenitor lineages,
characterized by the expression of essential transcription factors
for lineage commitment and terminal differentiation: (i) PIT1-
positive PSCs differentiate into GH/PRL/TSH-expressing cells,
(ii) TPIT-cells originate the ACTH-secreting subpopulation,
while (iii) LH/FSH-secreting cells derive from SF1 lineage (14).
Secretory cell types also include somato-lactotrophs which
release both GH and PRL, and are considered less differentiated
precursors of the mature cells releasing the specific hormone.
Neurohypophysis receives peptide hormones (anti-diuretic
hormone and oxytocin) via axonal terminals of neurons
projecting from the hypothalamus, and releases them under the
hypothalamic control.
Adenohypophysis also contains endothelial cells and
pericytes, and non-endocrine S100β-positive folliculo-stellate
(FS) cells which produce growth factors and cytokines regulating
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and sustaining hormonal cell activity by integrating paracrine
signals (15). FS cells maintain pituitary homeostasis, favoring the
maturation of stem/progenitor cells and have been considered as
putative PSCs (16, 17). Indeed, the fine tuning of number and
activity of secretory cell types in different physiologic conditions
requires high plasticity of the pituitary gland and is based on
the presence of stem and progenitor cells, which control cell
turnover and differentiation (18).
Pituitary Stem Cells in Cell Turnover and
Responses to Hormones
Adult pituitary gland plasticity grants continuous cell turnover
(homeostasis), and dynamically adapts its activity to either
physiological cues (during puberty somatotroph cell number
increase, or during pregnancy and lactation an increase
in lactotrophs is observed) or pathological damages, by
increasing specific hormone production. This process involves
the recruitment of non-hormonal pituitary stem/progenitor cells
(16), which are characterized by the expression of stem cell
markers (Oct4, Nanog), the growth as spheroids (“pituispheres”),
and the ability to differentiate into pituitary secretory cells. For
example, the activity of these subpopulations gives rise to the
generation of waves of novel corticotroph and gonadotroph cells
after adrenalectomy or gonadectomy (19, 20).
Putative mouse pituitary progenitors express the transcription
factor Sox2 and are mainly localized dispersed within anterior
pituitary parenchyma and in the marginal zone, a remnant
of Rathke’s cleft. Functionally, they grow in vitro as spheroids
and are able to differentiate into all hormone-secretory cell
types (21, 22). The major role of Sox2-expressing cells in adult
mouse pituitary regeneration and plasticity has been further
strengthened by the observation that these cells self-renew
and naturally give rise to secretory cells throughout organism
lifespan (23–25), even in response to selective ablation of mature
endocrine pituitary cells (23, 26). Sox2 expression has been often
associated with Sox9 and CD133 expression, as well as with
the activation of developmental pathways, essential for stem cell
homeostasis and embryogenesis. Although most studies have
been carried out using adult mouse pituitaries, the similarity
of the pattern of SOX2 expression in human pituitary, and the
close structural resemblance of the stem niche from rodents to
humans, allowed the extrapolation of the information from the
animal model to humans (27).
Undoubtedly, multiple human stem cell populations depend
on SOX2 activity for persistence and differentiation. However,
in adult rat or mouse pituitary besides Sox2-expression, cells
positive for Sox9, Nestin (28, 29), S100 (30, 31), E-cadherin, Oct4,
Prophet of PIT1 (Prop1) (32, 33), Paired-Related Homeodomain
Proteins 1 and 2 (Prrx1/2) (34–36), and glial cell line-derived
neurotropic factor receptor-α 2 (GFRα2) (32, 35, 37), have been
proposed as stem/progenitor candidates, with the expression
of the different markers sometime overlapping within the
same cell subset. Currently, only fragmentary evidence of
stem-like properties of these cell subpopulations is available,
being occasionally tested for the ability to undergo epithelial-
mesenchymal transition (EMT) (38), to form colonies (13),
and to retain multipotency (39). In rats, post-natal pituitary
stem/progenitor cells were detected in the marginal zone and/or
identified as GFRα2+/Sox2+/Sox9+ cell clusters scattered within
the parenchyma of anterior pituitary; hormonal modulation
at the middle of gestation increases the number of cells
expressing stemmarkers in the marginal zone, while at beginning
of lactation differentiated markers were predominant in the
parenchyma and correlated to changes in cell proliferation; this
observation supports the hypothesis that the PSC niche actively
drives physiological pituitary plasticity (40).
Among embryonic transcription factors correlated to
stemness, Prop1 has been detected in adult PSCs to regulate EMT
(32, 33, 38). In rat anterior pituitary, hormonal cell differentiation
is associated with Prop1 and Sox2 downregulation during post-
natal development (21, 29, 33, 41, 42). In addition, SOX2 and
PROP1 double positive cells, also expressing embryonic PRRX1
and PRRX2, have been detected in adult human pituitary gland
(34). Mouse Sox2/Prop1-expressing PSCs are characterized by
the co-expression of GFRα2, β-catenin, E-cadherin, as well Sox9,
and Oct4, spherogenesis ability in vitro, and low proliferative rate
in vivo after birth, suggesting their undifferentiated, stem-like
nature (32).
As observed for stem cells from different tissue,
Sox2+/Sox9+/E-cadherin+ PSCs have been detected within
specific niches, which in adult mouse and rat anterior pituitary
were identified in the marginal zone (21, 29, 32, 39, 41), and
within the anterior lobe parenchyma (21, 25, 42–44). A similar
organization and expression profile of PSCs has been described
in the human gland (27, 32), although their regulation, likely
involving soluble factors, cell surface proteins and extracellular
matrices, is still not completely clear (31, 42, 44–47).
Among gene and protein signatures of the cells populating
stem cell niches, the chemokine CXCL12 and its receptor CXCR4
are commonly detected. CXCR4 has been identified in different
adult organs, including neuroendocrine tissues; in particular this
receptor/ligand system is expressed in human normal anterior
pituitary (48, 49), in both hormone-secreting (50) and non-
hormonal cell types of humans and rodents (i.e., FS cells) (16,
51, 52). Post-natal mouse PSCs, isolated as side population
(SP) cells in flow cytometry experiments, show Cxcl12/Cxcr4
expression (29) as well as S100-positive cells, likely comprising
the Sox2+-stem/progenitor cells detected in the rat anterior
lobe (41, 52). CXCL12/CXCR4 chemokine system is crucial for
CNS development, functioning, and stemness maintenance (53),
being expressed in embryonic and adult CNS stem cells, and
playing a role in pituitary stem-related plasticity (54). CXCR4
is upregulated in putative PSCs (44, 52), and SP cells of mouse
pituitary gland (34). In the stem cell niches CXCL12/CXCR4 axis
acts as chemoattractant and trophic factor for several cell types
via paracrine and/or autocrine mechanisms (55), and induces
EMT in progenitors (47, 56); this activity was also described
in pituitary (51), further suggesting an association between its
expression/activity and the stem cell phenotype.
Moreover, tissue/organ regeneration after physical or
immunological injuries implies the activation of PSCs (57, 58)
as described in pathological conditions which frequently cause
transient or permanent hypopituitarism (e.g., altered embryonic
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FIGURE 1 | Expression of stem cell-associated markers in adult pituitary stem cell (PSC) and pituitary adenoma stem cell (PASC) populations. Adult PSCs exist within
normal anterior pituitary and have been characterized by the expression of a discrete number of stem cell markers, most of them showing overlapping expression with
Sox2-positive cell subset. Evidence supporting the presence of pituitary tumor stem cells is also based on enhanced stem cell marker expression. The figure
summarizes the main markers used to identify the stem cell phenotype and corresponding references.
formation, traumatic brain insults, tumor growth, or resection)
(59). Since these clinical conditions constrain patients to a
lifetime hormone replacement, a better understanding of the
PSC regenerative potential and the mechanisms involved,
could represent a therapeutic option for hypopituitarism.
Transgenic mouse models were used to induce ablation of
specific pituitary hormonal lineages to mimic pituitary injuries
and study the regenerative properties of PSCs (60). For example,
in GHCre/iDTR mice, diphtheria toxin (DT) treatment causes
the elimination of GH-secreting cells. These experimental
conditions trigger the activation of Sox2+ cells giving origin
to Sox2+/GH+ cell population (23), although this regenerative
capacity of the pituitary is time- and age-limited (58). Similarly,
the differentiation potential of PSCs was reported after lactotroph
ablation (23). Conversely, using an ACTH-secreting cell ablation
model, authors reported that self-duplication of residual
mature cells, rather than PSCs, is the predominant source for
corticotroph restoration/replacement in the adult (61).
More recently, in vitro 3D multicellular structures
(organoids), which better recapitulate phenotype and functions
of the original tissue (62), have been proposed as a new
experimental way to investigate PSC biology and differentiation
pathways upon injury-activated stimuli (63). Organoid cells,
derived from normal and GH-depleted adult mouse pituitary,
mainly express Sox2 and E-cadherin, as previously described
for PSCs (21, 32) and retain Sox2 after expansion in culture,
showing limited differentiation capacity. Organoids from cell
cultures of injured GHCre/iDTR pituitary show cystic structure,
low proliferative activity, immature pituitary phenotype and
alterations in specific pathways (i.e., Wnt/Lgr) as compared to
dense undamaged pituitary organoid models, thus representing
a valuable tool to study the regulation of putative PSCs in both
normal and activated conditions (63).
Overall, Sox2+ cells, persisting throughout life and being
able to differentiate into pituitary hormone-secreting lineages,
represent the most widely validated in vitro PSC model;
however, studies performed in different animal models did not
report a univocal phenotype, and the existence of a single or
distinct stem cell populations is not definitely proven. Therefore,
the expression of multiple markers (Gfrα2-3, Prop1, Sox2,
Oct4, Sox9, β-catenin, E-cadherin), outlined in Figure 1, might
reflect in vivo heterogeneity of both PSCs and committed
progenitor populations, indicating the existence of cell subsets
in the pituitary, different for origin, phenotype, activation
of transcription factors, or niche interactions, which display
different functions in adult human organ plasticity. Further
characterization of human adult PSCs will allow a better
understanding of the physiological and pathological roles of these
cell subsets.
CANCER STEM CELLS IN PITUITARY
ADENOMA
A detailed characterization of CSC-like subpopulations was
performed in the adamantinomatous craniopharyngioma, a
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low-grade pediatric pituitary tumor originating from Rathke’s
pouch, which may display an aggressive clinical course (64).
Moreover, the CSC hierarchical tumorigenesis model was also
proposed to be at the basis of the development of other
benign tumors, and, in particular, pituitary adenomas (PAs)
(54, 65, 66). As performed in other tumors, identification and
isolation of PA stem cells (PASCs) relies on immunostaining
followed by FACS or image microscopy (immunohistochemistry
or immunofluorescence) in order to detect surface stem markers
in post-surgical pathology preparations or, more recently, in in
vitro cell cultures enriched in stem-like subpopulations by flow
cytometry or growth in stem cell permissive media. However,
CSCs are mainly operationally defined, using functional assays
such as assessment of cell proliferation or clonogenic activity
(to detect sustained proliferative potential) and sphere formation
assay (as an index of self-renewal ability), Nonetheless, since
in vivo tumorigenic property still represents the main defining
parameter for CSCs, mouse xenograft is the most reliable method
for assessing the presence of CSCs in a cell culture. However,
in PAs, cell senescence, involved in preventing the malignant
features in these tumors, is believed to inhibit the development
of PAs in mouse models (67), and indeed not all the studies
were able to demonstrate this feature in mice, leading to the
establishment of alternative animal models, i.e., tumor growth in
zebrafish embryos (68).
The following paragraphs will highlight consensus and
diverging reports on these features in PASCs and the implications
for their definition. A comparative analysis of the data from the
different studies are summarized in Table 1.
Isolation of Putative Pituitary Adenoma
Stem Cells
Most reports describe the in vitro isolation of putative PASCs
through the subpopulation selection using stem cell-permissive
media originally used to isolate and cultivate neural stem cells.
In particular, beside few differences, a common, fundamental
feature is observed in all media formulations from the published
studies: the absence of serum and the presence of growth factors,
generally EGF and bFGF. Serum-free medium was already used
to enrich in CSCs, cultures from several different solid tumors
(79) and allowed to retain in vitro genotype and phenotype
features similar to the original tumor (80). In almost all the
studies to date published, these experimental conditions held to
isolate PA cells able to grow in suspension as spheroids, a feature
generally considered an in vitro index of self-renewal.
However, it has to be remarked that, to date, the success
rate of this procedure is still far from 100%. In the study of
Xu et al. two out of eight of the tested PAs gave rise to stem-
like cell cultures (69). In another study, 69.6% of cultured non-
functioning PAs (NFPAs) (n = 46) showed the formation of
non-adherent spheroids after 2 weeks of culture in stem cell-
permissive medium; sphere generation was significantly higher
in aggressive tumors as assessed by cavernous sinus invasion
(78). In our lab, we developed a similar protocol to isolate
and expand in vitro putative PASCs from GH-secreting PAs
(GHomas) and NFPAs post-surgical specimens (81), obtaining
a similar success rate. In particular, 68% of the PAs (n = 38)
were able to proliferate as spheroids when selected in stem-
cell permissive medium (77). Importantly, in this study we
demonstrated that PASC selection, performed either by growth in
stem cell-permissivemedium or by sorting for CD133 expression,
gives rise to cell subpopulations endowed with comparable stem
cell-like features; these results highlight the relevance of CD133
in PASCs, as also reported in CSCs from different malignant
tumors (82). A similar approach was described by Zhao et al.
who sorted CD133+ and NESTIN+ co-expressing cells from
dispersed PA cells. These cells represented up to the 3% of total
PA cells and were able to generate spheres for several passages
(83). In other reports, stem cell-permissive medium allowed the
selection of sphere-forming cells in cultures from all the 12 (71)
or 14 (84) tumor analyzed including GH-, ACTH-, FSH/PRL-
secreting PAs and NFPAs. Similar results were obtained in a
mouse model (Rb+/− mice), which spontaneously develops PAs:
the growth of explanted tumor cells in stem- permissive culture
conditions held the isolation of sphere-forming putative PASCs
(72). A stem-like cell subpopulation was also derived from three
human GHomas and three NFPAs, growing dispersed cells using
culture conditions developed for mesenchymal stem cell (MSC)
cultures, although these PASCs showed peculiar characteristics as
compared to the others studies (see below) (74).
A different approach was used in another study (73), in which
the same methodology used to isolate adult PSCs from normal
murine pituitaries was applied (85). Since one of the typical
features of cells with a stem-like signature is the overexpression
of ATP-binding cassette (ABC) multidrug transporters, which
confers resistance against toxic stimuli (included those exerted
by drugs), they analyze PA cultures for the ability to extrude,
via these transporters, the fluorescent DNA-binding dye Hoechst
33342, appearing in the FACS analysis as a “side population”
(SP). Interestingly, SP cells were isolated form all the 60
tested adenomas (GH- and ACTH-secreting, or NFPAs), with a
calculated presence of putative PASCs ranging from 0.5 to 2%
(mean 1.9%), with the occasional observation of a NFPA showing
up to 17.2%. SP cells grew as spheroids in vitro, even though only
short term proliferation was observed, and, to perform a more
detailed characterization of stem properties, SP cells derived from
the established murine corticotroph adenoma cell line AtT20
were analyzed (73).
Stem Cell Markers and Intracellular
Pathways in Pituitary Adenoma Cells
Although tissue-specific transcription factors can be identified
in normal stem cells from different tissues, normal stem
cells are generally defined by the expression of a common
subset of stemness-related factors (e.g., SOX2, NANOG, OCT4,
NOTCH, CXCR4/CXCL12, CD44, etc.) which confers the
peculiar properties of self-renewal and pluripotency, during both
embryonic development and adult stage (13). Candidate PASCs
also display expression of several markers used for stem cell
identification by immunophenotyping. For example, SOX2 and
NANOG are two pluripotency-associated transcription factors
expressed by embryonic and adult stem cells, involved the

























TABLE 1 | Isolation and functional characterization of pituitary adenoma stem cells.
References Xu et al. (69) Yunoue et al.
(70)
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maintenance of stem cells in various adult tissues, and, in mouse,
Sox2+ cells are involved in pituitary regeneration (26). NOTCH
signaling contributes to stem cell proliferation (86) and prevents
progenitor cells from premature differentiation (87), while
OCT4, essential during embryogenesis and to retain pluripotency
in the adult tissues, is overexpressed in CSCs of various cancers
conferring drug resistance (88). CD133 (prominin 1) is a
membrane glycoprotein involved in retinal development, whose
overexpression is related to aggressiveness of ovarian, colorectal,
prostate, and lung cancer, and glioblastoma, representing a
signature for putative CSCs in these neoplasms (89); the
chemokine CXCL12 and its receptors CXCR4/CXCR7 are
involved in self-renewal and migratory behavior of normal
stem cells and CSCs (90, 91) acting via autocrine/paracrine
mechanisms (52, 55). Importantly, SOX2, NESTIN, GFRα2,
among others were established as markers to identify normal
PSCs and progenitors (92). For example, SOX2 and OCT4
expression was detected in scattered cells within human normal
pituitary samples, while more diffuse expression was observed for
CXCR4 (77).
The evaluation of the expression pattern of above stem
markers, summarized in Figure 1, represents the basis for the
characterization of CSC isolated from PAs.
Stem Cell Markers in Histological Pituitary Adenoma
Preparations
The first evidence of the presence of putative stem-like cells
within PAswas obtained from histological preparations of human
tissues. CD133 was analyzed in a series of 70 PAs, observing
that 25.7 % of them showed positive immunolabeling, with
higher frequency in NFPAs as compared to GHomas (15/45 in
NFPAs vs. 3/25 in GHomas and prolactinomas) (70). After cell
dispersion and cytofluorimetric analysis, CD133-positive cells
were shown to represent an average of 2.9% of total adenoma cells
in NFPAs (n = 5), 0.8% in GHomas (n = 2) and 7% in the single
prolactinoma analyzed. However, CD133 expression levels were
not correlated with tumor size, or post-operative recurrence rate.
CD133+ cells also co-expressed NESTIN and, although with high
intertumor variability, CD34. However, no statistically significant
correlation between CD34 and CD133 expression was observed.
Wurth et al. identified, by immunofluorescence, the expression
of SOX2, OCT4, NESTIN, and CD133, in seven human GHoma,
and five NFPA samples, while NANOG and NOTCH1 were
detected in 25 and 50%, respectively, of the samples analyzed;
these markers restricted to subsets of cells diffuse within
tumor mass, but, in GHomas, do not co-localized with GH-
secreting cells (77). Subsequently, small cell subpopulations
expressing CD133 and NESTIN were identified in 12 human
prolactinomas by immunofluorescence analysis. Interestingly,
CD133 and dopamine D2 receptor (D2R) expression, analyzed
by FACS, segregate in different subpopulations (93). In another
series of human PAs, NOTCH 1–4 receptor subtypes, and their
ligand JAGGED1 were detected by RT-PCR, suggesting the
presence of a constitutive autocrine/paracrine NOTCH system
activation in a subset of tumor cells (94). In this study, NOTCH3
immunohistochemistry showed that NFPAs, prolactinomas,
GHomas, and ACTH-secreting PAs (ACTHomas) express the
protein in the cytoplasm and membrane of tumor cells. SOX2
expression was also detected by immunohistochemistry in about
50% of 16 PAs, with prevalent expression in GHomas and
prolactinomas (60% of cases) than in NFPAs (only 20% of cases)
(95). Transcriptomic analysis confirmed an increased expression
of NOTCH3 in human NFPAs compared to normal pituitaries
(96), as further demonstrated by other studies at both mRNA and
protein levels (97–99).
In a large cohort of 65 PA specimens, CXCR4 mRNA
was detected in 92% of GHomas and 81% of NFPAs,
whereas the ligand CXCL12 was identified in 63 and 78%
GHomas and NFPAs, respectively. These data were confirmed
by immunohistochemistry and immunofluorescence, in
GHomas and NFPAs showing higher level of expression than
normal human pituitary samples (48). Flow cytometry and
immunofluorescence analysis of 35 PAs (21 invasive and 14
non-invasive) also revealed that CXCR4 and CXCL12 expression
was significantly higher in the invasive subset than that of the
non-invasive PAs (100); conversely no correlation was observed
for other markers such as CD44 and CD147. Interestingly,
CXCR4 activation in the rat somato-prolactinoma GH4C1 cells
enhances proliferation and hormone release (101), suggesting a
pivotal role for this chemokine system in PA functioning.
Pituitary Adenoma Stem Cell Markers in Enriched
in vitro Cultures
One of the first study reporting the phenotypical characterization
of putative stem cells isolated by two PA cell cultures (one
from a GHoma and one from a NFPA) was performed by Xu
et al. (69). They obtained pituitary cell spheroids which express
OCT4, NOTCH4, JAG2, CD133, and NESTIN. Subsequently,
similar or partially overlapping results were obtained in many
different studies in which PASCs were obtained with different
experimental approaches. In detail, a second study showed that
sphere colonies derived from PAs express CD133, NESTIN and
other stem markers typical of neural cells: NCAM (neural cell
adhesion molecule) and neuron-specific class II β-tubulin (71).
Moreover, in agreement with previous studies, PASCs isolated as
SP, besides NESTIN, revealed the expression of other stem cell-
related markers, such as CD44, CXCR4, KIT, KLF4, and SOX2
(73). Importantly, EMT-related gene expression, such as TWIST,
ZEB1 and 2, and SNAI1 and 2 was up-regulated in candidate
PASCs, as compared to non-SP cells, while the epithelial marker
genes CDH1 and CLDN1 were down-regulated (73), indicating
that EMT is active in PASCs. The highest relative levels of some
EMT-associated genes (ZEB2, SNAI2, and TWIST1) occurred
in the SP derived from invasive PAs, further highlighting the
clinical implication of these regulatory pathways in PASCs
(Figure 2). However, the EMT activation in PASCs will require
further validation.
In agreement with these results, our group reported that
PASC-derived pituispheres express SOX2, OCT4, NESTIN,
CD133, NOTCH1, and CXCR4 in almost all the culture analyzed
(93, 100, 87, 91, and 100%, respectively), while NANOG
expression was confined to only half of the PAs (77). A partially
divergent result was reported by Orciani et al. in a subset of six
GHomas and six NFPAs, in which, together with the expression
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FIGURE 2 | Dysregulation of major stem cell pathways in candidate pituitary adenoma stem cells and their involvement in pituitary tumorigenesis. The diagram
depicts key signaling pathways in pituitary adenoma implicated in sustaining the putative pituitary adenoma stem cell populations and its functions in tumor
maintenance and progression. Several pathways including Notch, Sonic Hedgehog (SHh), Hippo and Wnt, which are tightly regulated in normal stem and precursor
pituitary cells, are aberrantly regulated in tumors, likely in defined subsets of cancer stem cells within pituitary adenomas. Signaling pathways are often linked to
epithelial–mesenchymal transition (EMT) in the gain of tumor stem cell properties, and migration ability. An overview of main receptors and transcriptional mediators
upregulated in pituitary adenomas is represented as well as significant effects on the pathogenesis of pituitary adenoma.
of pluripotency factors (OCT4, NANOG, KLF4, CD133, and
SOX2), the typicalMSC surfacemarkers were identified in PASCs
(74). Indeed, these cells were isolated using MSC-permissive
culturemedium and, in appropriate culture conditions, they were
able to differentiate into osteogenic, lipogenic, and chondrogenic
cell lineages. Subsequently, using similar cultures from different
tumors, these Authors reported that PASCs also express markers
reminiscent of EMT (75). Similarly, in a different study, PASCs
isolated from two GHomas, three prolactinomas, and two NFPAs
displayedMSC features, as far as morphology, cell surface marker
expression (CD73, CD90, CD105, CD44, and vimentin), and
differentiating ability into osteocytes and adipocytes (76). These
results, in line with reports on better characterized malignant
tumor CSCs, i.e., glioblastoma (102), suggest the existence
of different CSC subpopulations within PAs, characterized by
different identities and, possibly, functions and origin within
adult pituitary, although partially sharing pluripotency markers.
In another report (78), putative PASCs were isolated from
46 NFPAs and characterized for the expression of SOX2,
OCT4, and KLF4 mRNAs. SOX2 and NESTIN expression was
also confirmed by immunohistochemistry/immunofluorescence
experiments, in a subset of PASC-enriched cultures grown
as spheroids. Moreover, indirect immunofluorescence analysis
revealed the nuclear co-expression of the pituitary specific
transcription factor PROP1 and SOX2 in about 2–10% of cells,
while PROP1 was cytoplasmic in SOX2− cells, highlighting the
presence, within the culture, of heterogeneous populations of
stem (PROP1+/SOX2+/) and precursor (PROP1+/SOX2−) cells
Finally, the analysis of cells from 22 PAs of different subtypes
showed a preferential high expression of CD15, as compared to
CD133. Moreover, by comparative analysis within each tumor
cell culture, of CD15high and CD15low subpopulations, it was
reported that CD15high cells are also associated to higher SOX2
and PAX7 expression, and were detected in higher percentage in
recurrent PAs as compared to the matched primary tumor (84).
To date only one study formally described the in vitro
isolation of murine PASC, spontaneously originated from
pituitary intermediate lobe in Rb+/− mice. Isolated cells were
grown as spheroids and expressed Sox2, Nestin and CD133, as
well as Sca1, in line with what reported in normal PSCs (72).
Nevertheless, this study is particularly important since it implies
a common phenotype of PASCs, independent from the human or
murine origin.
Stem Cell-Related Pathway Activity in Pituitary
Adenoma Cell Cultures
Altogether, previous described literature supports the alteration
of stem cell regulatory pathways in cell subpopulations within
PAs. Among these, the dysregulation of NOTCH pathway was
associated with PA, being gene expression of components of its
signaling (e.g., HES1, HEY, NOTCH1, NOTCH2) upregulated
in the SP from human PA (73). However, functional data
Frontiers in Endocrinology | www.frontiersin.org 8 February 2020 | Volume 11 | Article 54
Würth et al. Pituitary Adenoma Stem Cells
able to clarify its role in PASC tumorigenesis are very limited,
and mainly obtained in established PA cell lines. To address
this issue, Zubeldía-Brenner et al. (103) used the rat somato-
prolactinoma cell line GH3 [previously showed be positive
for Notch1-4 (94)] to determine whether the inhibition of
Notch signaling would affect growth and angiogenesis of tumor
xenografts in immune-compromisedmice. For this purpose, they
used a γ-secretase inhibitor (DAPT), which prevents cleavage of
intracellular Notch domains and, consequently, modifies target
specific transcription factors in the nucleus. Interestingly, the
inhibition of Notch signaling led to tumor mass reduction
and decreased neoangiogenesis. In order to elucidate whether
putative PASCs with constitutive active NOTCH system could
be targeted by inhibition of this pathway, a significant research
work in tumor subtype-specific manner has still to be done.
Nevertheless, these recent data may support the downregulation
of NOTCH signaling as a potential therapeutic tool in aggressive
or resistant PAs.
Other studies identified a relationship between the expression
and/or activity of different specific stem cell markers in pituitary
tumorigenesis. The activity of SONIC HEDGEHOG (SHH)
pathway, crucial during embryogenesis and organ development,
differs among PA subtypes, being downregulated in NFPAs as
compared to normal pituitary tissues, while GLI1, one of the
transcriptional effectors that mediate SHH signal transduction, is
overexpressed in GHomas and ACTHomas (73, 104). Excess Shh
signaling increases both the proliferation of Sox2+ and Sox9+
adult mouse PSCs and the expression of ACTH, GH and PRL
in adult pituitary (105). SHH and its target gene GLI1 were
also shown to be overexpressed in GHomas, ACTHomas, and
prolactinomas, further supporting that excess SHH signaling
is involved in the development/maintenance of hormone-
producing PAs. SHH administration to the HP75 human PA cells
caused the upregulation of SOX2 and proliferation of β-catenin-
expressing cells. Similarly, the addition of WNT3a in SOX2-
expressing PA cells sustains cell proliferation. It was proposed
that SOX2 mediates crosstalk between SHH and WNT/β-
catenin pathways to promote the proliferation of PAs (106).
In fact, aberrant WNT/β-catenin activity has been observed in
pituitary tumors (107), and gene expression of components of
the pathway (LEF1, LGR5, TCF7L1) was identified in PA SP
cells (73).
The HIPPO kinase cascade is a crucial pathway that regulates
cell growth and fate in numerous organs, and may be implicated
in the regenerative response of PSCs (58). In mouse PSCs,
this signaling activity, in association with its effectors Yes-
associated protein (Yap) and transcriptional co-activator with
PDZ binding motif (Taz), was detected in Sox2-expressing
subpopulations. Moreover, overexpression of HIPPO pathway
components (i.e., large tumor suppressor homolog 2, LATS2,
and TEAD4), has been described in PA SP cells (73) as
well as in poorly differentiated pituitary tumors (null-cell PAs,
adamantinous and papillary craniopharyngiomas) which display
enhanced YAP/TAZ activity (108). Importantly, the activation
of HIPPO pathway, by silencing the kinase LATS1, inhibits
promoter activity of GH1 and PRL genes, correlating high
YAP/TAZ activity with repression of pituitary differentiation
(108). Using a genetic approach to perform gain- and loss-
of-function experiments in mice, it was shown that Yap/Taz
activation during development is essential for normal pituitary
formation from Sox2+ PSCs. However, postnatal upregulation of
Yap/Taz activity causes uncontrolled clonal expansion of Sox2+
pituitary cells, disruption of their differentiation, and formation
of aggressive NFPAs, highlighting that this regulatory signaling
cascade is a relevant component for both pituitary development
and tumorigenesis (109).
Figure 2 summarizes the signaling pathways and
transcriptional networks involved in PASC maintenance
and tumorigenesis.
Assessment of Biological and Functional
Activity in Putative Pituitary Adenoma
Stem Cells
As highlighted before, CSCs are not a single population within a
given tumor, but they set apart into subpopulations characterized
by heterogeneous phenotypes (110, 111). Thus, beside marker
expression, the characterization of these cells requires the
establishment of biological and/or functional specific activities.
In particular, by definition, CSCs should display: (i) self-renewal,
mainly assessed by serial sphere-forming ability, (ii) long term
proliferation in vitro, and (iii) capacity to differentiate into
specific cell types related to the tissue of origin.
In vitro Self-Renewal Activity
In vitro spherogenesis is a commonly accepted index of the self-
renewal ability of a cell population. Although all the studies
addressing the role of PASCs as PA-initiating cells, used the ability
to form pituispheres to identify these subpopulations, in order to
validate the CSC phenotype, this ability should be a persistent
feature of the isolated cells. This can be assessed measuring
the generation of secondary (tertiary, or more) spheres after
disaggregation of the initially generated spheroids. This ability
was indeed described in most of the previously mentioned
studies: Xu et al. reported that after up to 15 passages PASCs
were still able to generate spheroids (69); Chen et al. observed
that, after dispersion of PAs to single cells, primary spheres are
generated after 2–3 weeks in culture and that daughter cells
derived from the spheres formed secondary spheres within 2–
4 weeks after reseeding (71); Peverelli et al. showed that cells
from 46 PAs form primary spheres after about 2 weeks in stem
cell-permissive medium, with sphere-forming efficiency (SFE),
calculated in a subset of tumors, in about 2–5% of the plated cells.
Cells derived from primary spheres and re-plated as single cell
were able to generate secondary spheres with a SFE of about 4–
8%, while no tertiary spheres were obtained (78). In our study,
sphere formation occurred after 7–10 days in 14 out of 16GHoma
and NFPA cell cultures, but proliferation within spheroids lasted
for several weeks (77). In a subset of samples in which it was
calculated, SFE was in the range of 1.3–7%. Cells harvested from
disaggregation of 7 days living spheroids were able to generate
secondary spheres within 13 days culture in stem cell-permissive
medium, with a slightly higher SFE in secondary spheres as
compared to that of the primary spheroids derived from the same
PA (77). Similar data were obtained in PA cultures derived from
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the Rb+/− mice: spheres were generated starting after 3 days in
vitro and continued to grow up to 10–12 days. After dissociation,
although the number of viable cells declined, cells from primary
spheres generated secondary spheres displaying similar growth
rate, for up to 12 passages. As compared to non-stem population
(identified by the lack of Sca1 expression), PASCs showed four-
time higher propensity to generate spheroids (72).
Spheres also developed from SP cells isolated after dispersion
of PA tissues, while the main population was devoid of such
activity. However, SFE was very low, with only 2–4 per 20,000
cells seeded, which did not allow to have viable cells in a sufficient
number to test spherogenesis in further passages (73).
Proliferation and Migration Abilities
Primary cultures of non-stem PA cells have a very low
proliferative activity, with nomore than 1–2 in vitro cell divisions
(112, 113). Thus, sustained and long-lasting proliferation in vitro
may represent a relevant index to identify cell subpopulations
endowed with stem-like characteristics. However, only few
studies analyzed this feature: Wurth et al. reported that cells
derived from 11 PASC-enriched cultures proliferate up to 28 days
increasing up to 400% the initial number, although for longer
culturing time the proliferative potential declines. Conversely,
non-stem PA cell cultures barely duplicated once, and started to
degenerate from the second week in vitro (77). Peverelli et al.
reported that NFPA PASC spheroids contain a high percentage of
Ki67+ cells, which lasted up to 4 weeks, while the differentiated
cell counterpart retains a proliferative activity for no longer than
1 week (78). Similarly, stem-like cells derived from Rb+/− mice
PAs, characterized for Sca1 expression, exhibit a proliferative
advantage over Sca1− cells, evaluated up to 3 days in culture
and reaching a 4.4-fold increase in growth rate (72). Orciani
et al. reported a linear growth of mesenchymal PASCs for up
to 12 days, with a doubling time of about 20 h for the first
eight passages (74). However, at the 12th in vitro passage the
doubling time reached 40 h, further confirming, that PASCs tend
to lose the stem cell-like features, as observed in different in vitro
models (77). Megnis et al. reported a continuous proliferation
in all the 6 PASC-enriched cultures analyzed, up to 14 days
(76). Other studies were not able to observe a sustained in
vitro proliferation and did not analyze this parameter (73).
The limited in vitro growth of PASCs, although much more
prolonged as compared to non-stem PA cells, might either reflect
intrinsic features or technical limitations in the cultivation of
these cells. In this respect, the benign nature of PAs, in which
the activation of senescence program limits tumor expansion,
could determine the self-limiting growth of these cells in vitro.
Moreover, it should be considered that culture conditions for
PASCs are mainly adapted from CSC cultures of different tumors
(79), and may be inappropriate or insufficient to support their
continuous growth. Further studies are required to address
this issue.
CD133+ cells isolated from both GHomas and NFPAs also
possess a higher migratory activity as compared to CD133− cells
isolated from the same tumor (74). This observation provides a
direct support to the correlation previously reported of a higher
number of CD133+ cells in invasive PAs as compared to those
with a non-invasive clinical behavior (71).
Differentiation Ability
Stem cell are undifferentiated cells acting as a reservoir from
which differentiated cells origin to replace cells during normal
adult tissue turnover or after injuries. This feature is also
present in CSCs which are the source of all the “differentiated”
tumor cells forming the bulk of the tumor. In several tumors
CSCs possess a marked in vitro differentiation ability. For
example, glioblastoma CSCs, grown in the absence of growth
factors and in the presence of fetal bovine serum (FBS),
are able to differentiate into astrocyte- and/or neuron-like
cells (114). Contrasting results were reported as far as PASC
differentiation ability: in most studies this PA subpopulation does
not express pituitary hormones (69, 70, 77), while, in others,
the immunohistochemical detection of LH in Sox2+ cells within
spheroids was reported, although evidence of co-localization in
the same cells was not provided (78). However, relevant to the
CSC ability to originate all the cell populations composing the
tumor, few studies actually showed that PASCs, isolated from
hormone-producing tumors, can differentiate into hormone-
releasing cells in vitro. Xu et al. showed, using specific ELISAs,
that when shifted in differentiation medium (in which growth
factors were replaced by FBS) for 2 weeks, PASCs derived from
a GHoma released GH in response to GRF, and LH and FSH
when exposed to LHRH (69). This was not observed in the
same cells grown in stem cell permissive medium. However,
both stem-like and differentiated cells released PRL in response
to PRL-releasing peptide, and TSH in response to TRH. NFPA
PASCs also released LH in basal conditions, as also demonstrated
by Peverelli et al. (78), and, after differentiation, released both
LH and FSH after LHRH treatment. Thus, PASC differentiation
potential was demonstrated, but it was still unaddressed the
lack of a tumor-specific differentiation, since LH, FSH, and
TSH were also produced by GH-secreting PA culture. PASC
ability of to differentiate into cells with an adult pituitary cell
phenotype was tested evaluating GH production in 2 GHoma
PASC cultures after differentiation induced by shifting the
cells in FBS-containing medium for 10 days (77). In these
experimental conditions GH immunoreactivity, undetectable
in the cells kept in stem cell-permissive medium, was clearly
evident. Interestingly in the same cells the expression of some
stem cell markers (CD133, OCT4, NESTIN) was reduced after
differentiation, while others were retained (i.e., CXCR4). These
data clearly support the differentiation potential of these PASC
cultures, in which the loss of stemness markers is associated
to the induction of hormone production. However, when cells
were grown for 30 days in stem-permissive medium, few GH-
expressing cells were observed also in these conditions, although
in a lower number than observed after differentiation (77). Thus,
a low level of spontaneous differentiation may occur in the
PASC subpopulation, in line with the loss of proliferative activity
after prolonged in vitro culture (see above). Similarly, PASCs,
isolated from tumors developed in Rb+/− mice and grown
in the presence of growth factors, are completely hormone-
negative, but after 9 days of culturing in differentiation medium
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all six pituitary hormones were detected in the cultures (72).
Also in this experimental setting, stem cell markers Sox2 and
Sca1 were downregulated, although few Nestin+ cells were
observed in differentiated PASCs, sometime co-expressed with
hormones (72).
Other studies reported the occurrence of heterologous
type of differentiation. Differentiated PASCs were shown to
express neural (β-III tubulin), astrocytic (glial fibrillary acidic







phosphodiesterase, CNPase) markers (69, 71).
On the other hand, when PASCs were selected according to
MSC isolation procedures and characterized by the expression
of mesenchymal markers, differentiation follows this lineage
and not the pituitary-related phenotypes. In fact, shifting the
cultures in defined media, cells acquire osteogenic [expression of
alkaline phosphatase after 10 (74) or 21 (76) days], adipogenic
(presence of cytoplasmic lipid vacuoles after 14/15 days) (74, 76),
or chondrogenic (detection of safaranin-O staining after 30 days)
(74) phenotypes.
These latter studies further highlight the possibility that
different stem-like subpopulations may be present within PAs,
which can be preferentially expanded in vitro according to the
isolation procedure used. Thus, more in depth lineage studies are
necessary to address the cellular origin of these subpopulations.
In vivo Tumorigenic Ability
The ability to regenerate in animal models the tumor from which
stem cells were isolated is still the main feature which defines
CSCs (115). Thus, the tumorigenic ability is a required feature
also for PASCs. However, when benign, slow-growing tumors are
studied, the development of animal model is a critical issues and,
to date, contradictory results were reported.
Several of the previously analyzed studies did not address
this issue in the characterization of PASCs (70, 73, 74, 76),
while others used immunodeficient mouse models to perform
xenograft experiments, as commonly performed for CSCs from
malignant tumors (glioblastoma, breast cancer, mesothelioma,
osteosarcoma) (114, 116–119).
Xu et al. succeeded in inducing tumor development after
brain parenchyma injection of 10,000 cells from both the two
cultures of PASCs they isolated. Xenografts were slow-growing,
being detectable after 3 months from the inoculation, but still
expanding after 6 months (69). Interestingly, the nature of
the original tumor was retained since tumors originated from
GHoma-isolated PASCs showed expression of GH (and PRL),
which was not observed when PASCs derived from NFPA were
injected. Moreover, PASCs recovered from tumor xenografts
were expanded in vitro as spheroids and re-injected in mouse
brains, retaining tumorigenicity. Similarly, a small tumor mass
was observed 12 weeks after subcutaneous (s.c.) inoculation
of 10,000 cells from spheroid cells isolated from a single PA
(71). The resulting single tumor displayed low proliferation rate
(as for Ki67 labeling), histology resembling PA structure, and
expressed synatpophysin, but it was not further characterized.
Similar results were obtained by the intracranial injection in
nude mice of 10,000 CD133+/nestin+ PA cells, which gave rise
to tumors, detectable after 6 weeks from the graft (83). In
another study, one PASC culture from a null PA, sorted for
CD15 expression, was pseudo-orthotopically injected in the brain
of three mice (84). In agreement with the CSC theory, 50,000
CD15+ cells generated tumors when injected in the mouse brain,
while up to 500,000 CD15− cells were not tumorigenic. The
explanted tumors showed high number of mitosis and nuclear
atypia, and, in agreement with the histological subtype of the
non-secreting original tumor, immunoreactivity for pituitary
hormones was not detected. Comparing the original tumor with
the xenograft, both specimens were negative for GFAP, alpha-
smooth muscle actin, EMA, and TTF1, and, according to the
neuroendocrine derivation, both expressed synaptophysin and
CD56. Interestingly, desmin and myogenin were unexpectedly
expressed only in the xenograft but not in the original PA,
suggesting that CD15+ PASCs possess a microenvironment-
dependent multi-lineage potential (84).
Conversely, Mertens et al. failed to demonstrate
tumorigenicity of PA cells in vivo by xeno-transplantation
in immunodeficient mice, regardless their hormonal phenotype.
In these experiments small tumor pieces were implanted s.c. or
under the kidney capsule in different mouse models: SCID mice,
or the more immunodeficient NOD–SCID and NOD-SCID
IL2rγnull (NSG) mice, which lack mature T, B, and natural killer
cells. Tumor specimens apparently survived for 3–4 months
after implantation but no growth was detected. Similar negative
results were also obtained using xenografts of dissociated PA
cells (73).
Also in our experience, we did not detect tumor development
within 8 months from the injection of PA cells that fully
accomplish the in vitro criteria for CSC definition (i.e.,
stem marker expression, undifferentiated phenotype and
differentiation ability in hormone-producing cells, high
proliferation potential, self-renewal); similar negative results
were observed after grafting the cells either s.c. into the flank of
animals in the presence of Matrigel (20,000 cells, from 2 PAs) or
pseudo-orthotopically in the striatum (50,000 cells, from 4 PAs)
(77). Thus, we used a different animal model: zebrafish embryos,
which allow the evaluation of two relevant CSC features which
define PASC tumorigenicity: invasive and angiogenic potential
(120). PASCs from 5 PAs were xenografted into embryos of the
Tg(fli1:EGFP)y1 zebrafish line that express EGFP in endothelial
cells, thus allowing to detect whether neovessels are formed
in proximity of the injected cells. PASCs were stained with a
red fluorescent dye, to follow their migration activity. In this
model, only a 500 cells/embryo are required and all the events
occur within 2–3 days. Grafted PASCs were easily detected soon
after the injection and, when recovered after 48 h, confirmed
the human nature and CD133 expression. However, after 24 h
injected PASCs start to migrate outside the tumor cell mass,
invading the yolk and the caudal areas. Moreover, at odd with
control embryos, grafted embryos showed the sprouting of
new vessels from the subintestinal vein plexus, which were
directed toward the tumor cells, demonstrating the induction of
in vivo neo-angiogenesis. Similar results were also reported by
Peverelli et al., who grafted sphere-derived cells from 2 NFPAs
in zebrafish embryos. After 24 h, tumor cells from both tumors
migrated outside the site of the injection confirming an invasive
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ability. Moreover, also in this study injected spheroid-derived
cells stimulated the formation of endothelial sprouts from the
subintestinal vessels plexus in 1/3 animals (78).
Finally, tumorigenic ability was also reported for PASCs
derived from Rb+/− mice, although this occurrence was
somehow expected since they contain the specific genetic
alteration responsible for the formation of these adenomas
(72). In these experiments Sca1+ and Sca1− cells were
compared, demonstrating that the stem-like cell subpopulation
was endowed with higher tumorigenic potential when injected
in the striatum of NSG mice. Importantly, although injected
cells were hormone-negative, after in vivo tumor development
multiple hormones were detected in 91% of the 11 tumors
analyzed. Sca1 expression was abolished in almost all the tumors,
whereas other stemness markers were retained (Nestin, CD133,
Sox2) in subsets of cells, altogether with the astrocytic marker
Gfap (72).
DRUG SENSITIVITY OF PITUITARY
ADENOMA STEM CELLS
One of the most relevant information that can be obtained by
identification of CSC from different tumors, is the possibility
to analyze, with good translational potential, the sensitivity of
this subpopulation to traditional or innovative pharmacological
treatments. For example, studies on CSC from glioblastoma,
breast cancer or osteosarcoma (119, 121–123), demonstrated
a higher sensitivity of this subpopulation to metformin, as
compared to “differentiated” tumor cells, determining the
development of a drug repositioning approach (124, 125). In
particular, while it is well-accepted that stem-like cells are
particularly resistant to classical cytotoxic drugs due to the
overexpression of drug-extruding pumps and DNA-repairing
enzymes (110), in CSC cultures from different tumors the
sensitivity to molecular-targeted drugs, in particular to tyrosine
kinase inhibitors, is retained (114, 126).
In line with these premises, PASCs, isolated as SP, showed
1.5-fold up-regulation of the multidrug transporters ABCB1 and
ABCG2 (73), thus suggesting their ability to extrude cytotoxic
drugs. Accordingly, Xu et al. reported that PASCs from a
GHoma were insensitive to both carboplatin and etoposide (69)
and temozolomide resistance was described in another study
(66). Interestingly, in a drug repositioning study, in vitro and
in vivo treatment with disulfiram, a clinically approved drug
for the treatment of alcoholism, sensitizes CD133+/nestin+
PASCs to temozolomide cytotoxicity, preventing drug-induced
DNA damage repair by inhibiting O-6-methylguanine-DNA
methyltransferase expression (83). Although CSC resistance to
cytotoxic drugs is still a relevant issue in the treatment of
all types of tumor, including aggressive PAs, PASCs might
retain sensitivity to biological treatments. Thus, the sensitivity
to commonly used drugs for PAs, somatostatin and dopamine
agonists, and the expression of their receptors were tested in
PASC subpopulations.
Both Wurth et al. and Peverelli et al. studies compared, in
adenoma tissues and in PASC-enriched spheroids, the expression
of somatostatin (SSTR) and dopamine (D2R, dopamine receptor
type 2) receptors, which are targeted by currently used
pharmacological treatments (i.e., SSTR2 and SSTR5, which are
activated by lanreotide and octreotide, and D2R, activated
by cabergoline) (77, 78). In the first study both SSTR2 and
SSTR5 were expressed by the original GH-secreting tumors and
within the analyzed sections, small groups of putative PASCs
(immunopositive for NESTIN) also express SSTR2. Hence, it
was suggested that these cells are not completely undifferentiated
but could represent a progenitor cell subpopulation, expressing
relevant regulatory neuropeptide receptors. This possibility was
confirmed by in vitro studies on PASC spheroids which were
mainly formed by cells co-expressing NESTIN, SSTR2 and
SSTR5; moreover, also OCT4+/D2R+ double positive cells were
detected in spheroids (77). Similar results were obtained by
Peverelli et al., who reported the expression of mRNAs for
SSTR2 and D2R, in both histological preparations and spheroids
fromNFPAs, evaluated by RT-PCR. Unexpectedly, SSTR5mRNA
was undetectable in spheroids although expressed in all tissues
analyzed (78). The expression of all the five SSTRs was analyzed
and compared with the original tumors also in PA MSCs derived
from six GHomas and six NFPAs (75), although a different
picture was reported. Mesenchymal PASCs derived from both PA
subtypes express SSTR1 at the highest level, while GHomas show
higher expression of SSTR1–4–5 than NFPAs, and lower level of
for SSTR2–3 was detected in both subtypes.
PASC expression of these pharmacologically relevant
receptors prompted the analysis of their possible modulation
to induce antiproliferative effects. In NFPAs, the role of SSTR2
and D2R activation in mediating antiproliferative signals was
analyzed using two selective agonists: BIM23120 for SSTR2 and
BIM53097 for D2R (78). The analysis was performed by BrdU
incorporation assay either soon after cell dispersion (day 3)
or after 30 days in vitro, when PASC-containing spheres were
completely formed. Interestingly, a different responsivity among
the cultures was observed, with about 33% of tested adenomas
showing reduced proliferation in response to BIM23120, and
43% to BIM53097. Sensitive tumors showed a similar response
in both culture conditions, indicating that drug sensitivity was
already present within tumors and not acquired during the
in vitro selection and expansion. On the average, although
variability among the cultures was observed, as expected,
BIM23120 (10 nM for 72 h) reduced DNA synthesis in the
spheroids by 65%, while BIM53097 by 45% (78). Moreover, both
drugs increased spheroid cell expression of the cyclin-dependent
kinase inhibitor p27Kip1 and decreased cyclin D3 content,
as molecular correlate of the antiproliferative effects of these
receptors, as already reported for SSTRs (127). Importantly, no
difference in the frequency of sphere formation among drug
sensitive and resistant adenomas was observed, although the
former were larger in size (78). Wurth et al., in light of the
co-expression of SSTR2, SSTR5, and D2R in the same spheroids,
used the MTT reduction assay to test the antiproliferative
effects mediated by these receptors using an innovative chimeric
SSTR2/SSTR5/D2R agonist, named BIM23A760 (128). In all the
cultures analyzed, BIM-23A760 (1 nM, for 24 h) inhibited growth
of spheroid-derived PASCs, reaching a statistical significance in
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TABLE 2 | Drug sensitivity of pituitary adenoma stem cells.
PASC origin PA histotype Drug Target (s) Effect References
HUMAN GH-oma Carboplatin DNA alkylation Drug resistance (69)
Etoposide Topoisomerase II Drug resistance
HUMAN GH-oma Temozolomide DNA alkylation Drug resistance (66)
HUMAN n.s. Temozolomide DNA alkylation Drug resistance (MGMT-dependent) (83)
Disulfiram ALDH Cell sensitization to temozolomide
HUMAN NFPA BIM23120 SSTR2 Anti-proliferative (78)
BIM53097 D2R Anti-proliferative
HUMAN NFPA BIM23A760 SSTR2,5-D2R Anti-proliferative (77)
HUMAN GH-oma Somatostatin SSTR1-5 Anti-proliferative (75)
Octreotide SSTR2,5 Anti-proliferative
Pasireotide SSTR1,2,3,5 Anti-proliferative
HUMAN NFPA Somatostatin SSTR1-5 No effect (75)
Octreotide SSTR2,5 No effect
Pasireotide SSTR1,2,3,5 No effect
MOUSE AtT20 cells (ACTH-oma) Plerixafor CXCR4 Inhibition of EMT-associated motility and xenograft tumor growth (73)
PASC, pituitary adenoma stem cell; PA, pituitary adenoma; MGMT, O-6-methylguanine-DNA methyltransferase; ALDH, aldehyde dehydrogenase; SSTR, somatostatin receptor; D2R,
dopamine receptor 2; n.s., not specified.
6 out of 7 PAs (ranging from −14 to −30% of vehicle-treated
controls), independently from the length of the period of growth
in vitro (analogous results were obtained in cultures lasting from
7 to 30 days) (77). An indirect evidence of the antiproliferative
activity of D2R in PASCs was provided in D2R knockout mice,
which develop prolactinomas starting at 6–8 months of age,
and whose tumors show higher colony forming activity and
a 2.4-fold increase in Sox2+ cells than the WT glands (73).
An unexpected difference in SSTR agonist sensitivity between
mesenchymal PASCs derived from GHomas and NFPAs, was
also reported (75), using native somatostatin (1µM), which
activates all the five SSTRs, octreotide, able to bind SSTR2 and
SSTR5, and pasireotide, which activate all SSTRs but SSTR4. In
fact, using both XTT test and direct cell count, a statistically
significant inhibition of proliferation was observed with all
the agonists in PASCs derived from GHomas after 72 or 144 h
of treatment (max inhibition about−40% for both octreotide
and pasireotide), without affecting EMT or the induction of
apoptosis. Conversely, no effects were detected in mesenchymal
PASC from NFPAs, although SSTRs were expressed in these
cells, and previous studies reported antiproliferative activity of
somatostatin, octreotide, and pasireotide (112, 129, 130).
Finally, a different experimental model using PASCs isolated
as SP from tumors originating from the murine ACTHoma
cell line AtT20 (73) was used to demonstrate the role
of the chemokine CXCL12 (131) in PASC proliferation.
The inhibition of CXCR4, the CXCL12 receptor, using the
clinical approved CXCR4 antagonist plerixafor, reduced EMT-
associated PASC motility in vitro, and xenograft tumor growth
in vivo (73).
All these data (summarized in Table 2) support the notion
that in PASCs, although isolated from different PA subtypes, with
different procedures, showing an undifferentiated phenotype,
express most of the membrane receptor systems involved in
pituitary cell stimulation (CXCR4) or inhibition (SSTRs, D2R)
of cell proliferation are expressed and functioning. Thus, their
modulation may represent a valuable pharmacological goal for
this otherwise drug-resistant subpopulation.
CONCLUSIONS AND FUTURE
PERSPECTIVES
From the literature we reviewed it is clear that, although
consistent information is currently available concerning the
actual existence of PASCs, many unsolved questions will need to
be further explored.
Notwithstanding the highlighted differences among the
published studies, the presence of stem-like cells in benign
tumors seems to be a confirmed notion. In particular, the
reported cell heterogeneity in PAs, a tumor type which by
definition is considered monoclonal in origin, further reinforces
this assumption. However, the divergent differentiation fate
of PA cells during tumor development (retaining of stem-
like phenotype, differentiation in hormone producing cells,
acquisition of mesenchymal or neural features) rises the relevant
issue of which factors actually control this transition, and the
identification of possible stem cell niche(s) within the tumor
mass where PASC can self-renew and act as reservoir for the
bulk of tumor cells. To date, although some tumor areas were
identified as putative PA niches, no formal demonstration has
been provided. Importantly, although discrepancies among the
papers that analyzed PASC features are clearly related to the
procedures (different permissive media, side-populations, etc.) or
the model (human PA of different subtypes, or mouse tumors)
used, it is also evident that multiple stem-like cell populations
may exist within PAs. Thus, it is very important to define the
characteristics of these cells not only as far as the biological
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features are concerned, but also to address whether different
PASC subpopulations co-exist in the same tumor or different
PAs develop from stem-like cells with distinct phenotypes. In
this respect, another unsolved issue is the actual cell of origin
(the real tumor stem cell) of PAs. While in the past most
evidence was pointing out the role of FS cells, now it seems
more likely that oncogenic transformation should occur in adult
PSCs, ormore differentiated pituitary progenitors. In this respect,
novel technologies, including single cell RNA sequencing, may
provide a significant contribution to address the question
regarding the origin of different PASC populations within PAs,
as recently performed in adult pituitaries (132). In this context,
the complete characterization of the different PA subpopulations
will allow the identification of the bases of the differential
efficacy of cytotoxic and biological pharmacological treatments
on PASCs. In fact, although cytotoxic drugs are scarcely effective
on PASCs, as expected in putative CSCs, these cells express
SSTRs and D2R and are responsive to the respective agonists.
Considering that the clinically approved receptor agonists, such
as octreotide, lanreotide, pasireotide, and cabergoline, display
both anti-secretory and, although less defined, antiproliferative
activities (133), it is conceivable that these dual effects may
involve the modulation of receptors in different PA cell subsets:
the former likely mainly acting on differentiated cells, and the
latter on PASCs. Further studies trying to clarify this issue are
most warranted.
Another relevant concern is the identification of mechanisms
controlling PASC proliferation, self-renewal, and differentiation.
Recently a role of miRNA in pituitary tumorigenesis was
proposed (134, 135). miRNAs are small non-coding RNAs that
post-transcriptionally modulate gene expression, and whose
expression is altered in several human neoplasia. For example,
relevant for the topic of this review, a differentmiRNA expression
pattern was observed in NFPAs and normal pituitary (136)
with a significant influence on stem cell-related pathways, such
as NOTCH (137). The field of miRNA is rapidly evolving
and its application to different PASC populations might
provide important novel information concerning the pathogenic
mechanisms activated in these cells to originate PAs.
Finally, a crucial issue for PASC research is the demonstration
of their tumorigenic potential, a required feature to define
putative CSCs. The development of animal models using human
PA cells is also extremely relevant to provide pharmacological
preclinical clues to be translated in clinical studies. As discussed
in the previous paragraph, this topic is very puzzling using
traditional mouse models, and novel approaches, such as
zebrafish embryo, can address only few aspects of this matter
(i.e., neoangiogenesis and cell migration). Recently, development
of 3D organoid systems (63), derived from Sox2-expressing
normal mouse pituitary cells allowed to maintain long-term
growth and stem-like phenotype during the expansive culture
but also to the ability to differentiate into hormone-producing
subpopulations. The application of this methodology to PAs
may contribute to definition of the actual tumor-initiating
subpopulation, the cellular and molecular pathways underlying
tumor growth and the possible acquisition of invasive features,
overcoming limitations observed using animal models.
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